1. Lasagna, L. The development and regulation of new medicines. Science 200, 871–873 (1978).
2. Severson, J. A. Hearing Testimony Oversight hearing on 'Gene Patents and Other Genomic Inventions,' House Committee on the Judiciary, Subcommittee on Courts and Intellectual Property, July 13, 2000. J. Assoc. Univ. Technol. Managers 12, 1–8 (2000).
3. Milne, C. -P. Orphan products-pain relief for clinical development headaches. Nature Biotechnol. 20, 780–784 (2002).
4. Shulman, S. R., DiMasi, J. A. & Kaitin, K. I. Patent term restoration: the impact of the Waxman–Hatch Act on new drugs and biologics approved 1984–1995. J. Biolaw Bus. 2, 63–68 (1999).
5. Milne, C. -P. & Bergman, E. Fast track product designation under the Food and Drug Administration Modernization Act: the industry experience. Drug Inf. J. 35, 71–83 (2001).